Placenta extract shows promise for liver disease in new trial
NCT ID NCT06493799
First seen Feb 23, 2026 · Last updated May 24, 2026 · Updated 20 times
Summary
This study tests a medicine made from human placenta, called LAENNEC, in people with chronic liver disease. It compares giving the medicine as an IV drip versus a shot under the skin. The main goal is to see if the IV form lowers liver enzyme (ALT) levels more effectively over 6 weeks. About 226 adults aged 19–70 with fatty liver disease and elevated ALT are being recruited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LIVER DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
GC wellbeing
RECRUITINGYongin-si, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.